Clinical trial · Observational
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
A Pilot Study in Cancer Patients With Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in the Upper Extremity Treated With Low Molecular Weight Heparin (LMWH) and Apixaban (Catheter 3)
NCT03100071CI-TRIAL-00053051unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Patients | — | UNRESOLVED | — |
| Central Venous Catheter Thrombosis | — | UNRESOLVED | — |
| Upper Extremity Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apixaban | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Central Line Failure
- timeFrame
- within 3 months of study follow-up
- description
- Infusion failure that does not respond to 2 milligram (mg) tissue Plasminogen Activator (tPA)
Secondary outcomes (2)
- measure
- Recurrent Venous Thromboembolism (VTE)
- timeFrame
- within 3 months of study follow-up
- description
- recurrence of blood clot either in leg or lung or both
- measure
- Bleeding
- timeFrame
- within 3 months of study follow-up
- description
- Major bleeding, clinically relevant minor bleed, death, time to central line failure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female \> 18 years of age. 2. Symptomatic acute upper limb thrombosis in the axillary, subclavian or internal jugular veins, with or without pulmonary embolism, associated with central venous catheter objectively documented by compression ultrasonography, venogram or Computerized Tomography (CT) scan. 3. Diagnosis of active malignancy, as defined by patients who are either receiving active treatment, or have metastatic disease or who have been diagnosed within the past two years. 4. Willing to provide written informed consent. Exclusion Criteria: 1. Presence of dialysis catheters 2. Active bleeding or high risk for major bleeding 3. Platelet Count \< 75 x 109/L 4. Creatinine Clearance \< 30 mL/min 5. Currently on other anticoagulant with therapeutic intent for another indication 6. Pulmonary embolism accompanied by hemodynamic instability or oxygen requirement 7. Inability to infuse through the catheter after a trial of intraluminal thrombolytic therapy (2 mg tPA). 8. Patients with Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) or multiple myeloma with a bone marrow or stem cell transplant planned within the next 3 months 9. Treatment for current episode \> 7 days with any acceptable anticoagulant therapy 10. Concomitant use of p-glucoprotein and Cytochrome P450 3A4 (CYP3A4) inhibitors (for example azole antifungals such as ketoconazole) or inducers (for example rifampicin, antiepileptics) 11. Recent coronary artery stent requiring dual anti-platelet therapy (for example acetylsalicylic acid \[ASA\] and Plavix) 12. If female of childbearing potential: pregnancy and/or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.